IFC Advisors LLC Has $277,000 Stock Holdings in Boston Scientific Corporation $BSX

IFC Advisors LLC boosted its holdings in shares of Boston Scientific Corporation (NYSE:BSX) by 15.5% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,578 shares of the medical equipment provider’s stock after buying an additional 346 shares during the period. IFC Advisors LLC’s holdings in Boston Scientific were worth $277,000 as of its most recent SEC filing.

Several other institutional investors have also recently bought and sold shares of BSX. 1248 Management LLC purchased a new stake in shares of Boston Scientific in the first quarter valued at about $26,000. Y.D. More Investments Ltd purchased a new stake in shares of Boston Scientific in the first quarter valued at about $27,000. Sound Income Strategies LLC raised its holdings in shares of Boston Scientific by 90.9% in the second quarter. Sound Income Strategies LLC now owns 252 shares of the medical equipment provider’s stock valued at $27,000 after purchasing an additional 120 shares during the last quarter. Oliver Lagore Vanvalin Investment Group bought a new position in Boston Scientific during the second quarter valued at about $37,000. Finally, Activest Wealth Management grew its position in Boston Scientific by 6,216.7% during the first quarter. Activest Wealth Management now owns 379 shares of the medical equipment provider’s stock valued at $38,000 after buying an additional 373 shares during the period. Institutional investors and hedge funds own 89.07% of the company’s stock.

Analyst Ratings Changes

Several equities analysts recently weighed in on the stock. Oppenheimer upgraded shares of Boston Scientific from a “market perform” rating to an “outperform” rating and increased their price target for the company from $118.00 to $125.00 in a research report on Monday, September 8th. BTIG Research increased their price target on shares of Boston Scientific from $127.00 to $132.00 and gave the company a “buy” rating in a research report on Wednesday, October 1st. Royal Bank Of Canada reiterated an “outperform” rating and set a $125.00 target price on shares of Boston Scientific in a research report on Monday, September 29th. Wells Fargo & Company increased their target price on shares of Boston Scientific from $118.00 to $124.00 and gave the stock an “overweight” rating in a research report on Thursday, July 24th. Finally, Leerink Partnrs upgraded shares of Boston Scientific to a “strong-buy” rating in a research report on Monday, June 16th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat, Boston Scientific has a consensus rating of “Buy” and an average target price of $120.71.

Boston Scientific Trading Down 0.5%

Shares of BSX opened at $94.92 on Tuesday. The firm’s 50 day simple moving average is $101.75 and its 200 day simple moving average is $101.84. The company has a market capitalization of $140.64 billion, a P/E ratio of 56.50, a P/E/G ratio of 2.30 and a beta of 0.61. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.37 and a quick ratio of 0.82. Boston Scientific Corporation has a 1-year low of $80.64 and a 1-year high of $109.50.

Boston Scientific (NYSE:BSX) last announced its earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share for the quarter, beating analysts’ consensus estimates of $0.72 by $0.03. The business had revenue of $5.06 billion for the quarter, compared to the consensus estimate of $4.89 billion. Boston Scientific had a net margin of 13.55% and a return on equity of 19.21%. Boston Scientific’s quarterly revenue was up 22.8% on a year-over-year basis. During the same period last year, the firm posted $0.62 earnings per share. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. Sell-side analysts forecast that Boston Scientific Corporation will post 2.85 earnings per share for the current fiscal year.

Insider Activity at Boston Scientific

In other news, Director Edward J. Ludwig sold 4,000 shares of the business’s stock in a transaction that occurred on Friday, July 25th. The shares were sold at an average price of $106.03, for a total value of $424,120.00. Following the completion of the sale, the director directly owned 18,479 shares in the company, valued at approximately $1,959,328.37. The trade was a 17.79% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Yoshiaki Fujimori sold 2,901 shares of the business’s stock in a transaction that occurred on Tuesday, July 29th. The stock was sold at an average price of $106.99, for a total transaction of $310,377.99. Following the completion of the sale, the director owned 2,081 shares of the company’s stock, valued at approximately $222,646.19. The trade was a 58.23% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 174,214 shares of company stock valued at $17,972,457. Company insiders own 0.50% of the company’s stock.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.